Skip to main content
    S

    Savara Inc (SVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.83
    +0.45 (+10.27%)

    Market Cap: $957.44M

    Last updated: Nov 06, 2026 at 4:39 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(24/39)
    Avg Surprise
    -6.43%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.23 - $-0.15
    6 analysts
    EPS Revisions
    1
    0
    7d
    1
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.15-14.2%
    60d ago$-0.16-8.3%
    30d ago$-0.16-8.3%
    7d ago$-0.170.0%
    Current$-0.17
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.36 - $-0.15
    6 analysts
    Revenue Consensus
    $2M
    Range$0 - $6M
    9 analysts
    Last 12 of 39 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.20$-0.36 - $-0.15--6--
    Sep 26EST
    		-$-0.17$-0.23 - $-0.15--6
    1
    4
    30d
    		-
    Jun 26
    Reported Aug 11
    		$-0.16$-0.14$-0.17 - $-0.13-14.29%Miss5
    0
    1
    30d
    		-14.3%
    Mar 26
    Reported May 12
    		$-0.15$-0.12$-0.13 - $-0.11-24.43%Miss6
    0
    2
    30d
    		-22.7%
    Dec 25
    Reported Mar 13
    		$-0.13$-0.12$-0.12 - $-0.11-8.33%Miss6
    1
    3
    30d
    		+0.0%
    Sep 25
    Reported Nov 12
    		$-0.14$-0.13$-0.14 - $-0.12-7.69%Miss5
    0
    3
    30d
    		-27.3%
    Jun 25
    Reported Aug 13
    		$-0.14$-0.12$-0.13 - $-0.11-16.67%Miss5
    2
    0
    30d
    		-16.7%
    Mar 25
    Reported May 13
    		$-0.12$-0.13$-0.14 - $-0.12+6.25%Beat5
    0
    2
    30d
    		-9.1%
    Dec 24
    Reported Mar 27
    		$-0.13$-0.11$-0.12 - $-0.10-18.18%Miss5
    0
    1
    30d
    		-44.4%
    Sep 24
    Reported Nov 12
    		$-0.11$-0.11$-0.12 - $-0.10+0.00%Beat6
    No revisions (30d)
    		-10.0%
    Jun 24
    Reported Aug 12
    		$-0.12$-0.11$-0.12 - $-0.10-9.09%Miss6
    No revisions (30d)
    		-71.4%
    Mar 24
    Reported May 9
    		$-0.11$-0.10$-0.11 - $-0.09-10.00%Miss6
    No revisions (30d)
    		-57.1%
    Dec 23
    Reported Mar 7
    		$-0.09$-0.10$-0.12 - $-0.09+10.00%Beat6
    0
    1
    30d
    		-28.6%
    Sep 23
    Reported Nov 9
    		$-0.10$-0.07$-0.08 - $-0.07-42.86%Miss4
    No revisions (30d)
    		-42.9%

    Key Metrics

    Valuation
    P/E Ratio-8.37EV/EBITDAN/A
    Price/FCF-11.07xFCF Yield-9.04%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-105.50%ROIC-63.33%
    Financial Health
    Debt/Equity0.21xInterest CoverageN/A
    Current Ratio10.13xQuick Ratio10.13x
    Trading Statistics
    Beta0.30Avg Volume2.44M
    52-Week High$7.0052-Week Low$3.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.75
    SMA 20$4.70
    SMA 50$4.98
    SMA 200$5.36
    EMA 10$4.70
    EMA 20$4.75
    EMA 50$4.94
    EMA 200$5.11

    MACD

    Line: -0.08Signal: -0.09Hist: 0.02

    ADX

    ADX: 17.4+DI: 20.2-DI: 24.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down60.0
    PSAR$5.12

    Bollinger Bands

    Upper Band$5.08
    Lower Band$4.31
    %B Position1659%(Upper)
    Band Width0.67

    RSI (14-Day)

    Neutral
    50.9

    Momentum Oscillators

    Stoch %K49.1
    Stoch %D51.2
    Williams %R-30.3
    ROC (10d)14.5%
    Momentum0.61
    CCI (20d)0.6
    MFI (14d)47.7

    Volatility Measures

    ATR (14d)$0.30(6.3%)
    StdDev (20d)0.19
    Hist Vol73.1%(High)

    Volume Flow

    VWAP$4.71
    OBV-28.0M
    AD Line-37.1M
    CMF (20d)-0.157

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.9x
    VWMA (20d)$4.68

    Pivot Points

    R3$4.88
    R2$4.76
    R1$4.57
    Pivot Point$4.45
    S1$4.26
    S2$4.14
    S3$3.95

    Advanced Oscillators

    TSI-7.79
    Ultimate Osc45.5
    KST-52.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$272,000$0$0$0$0$0
    Cost of RevenueN/A$66,000$40,000$20.59M$385,000$905,000$70,000$20.31M$600,000$1.30M$66,000$13.87M
    Gross ProfitN/A$-66,000$-40,000$-20,592,000$-385,000$-905,000$-70,000$-20,311,000$-600,000$-1,303,000$-66,000$-13,867,000
    Operating Expenses$40.97M$38.92M$33.39M$9.66M$31.05M$27.53M$31.10M$6.05M$22.59M$21.17M$17.56M$4.18M
    R&D$21.95M$23.40M$20.90M$20.59M$20.75M$19.16M$23.29M$20.31M$17.62M$16.81M$12.75M$13.87M
    SG&A$18.99M$15.53M$12.53M$9.63M$10.65M$9.25M$7.85M$6.01M$5.54M$5.64M$4.85M$4.15M
    Operating Income$-40,965,000$-38,990,000$-33,430,000$-30,255,000$-31,440,000$-28,435,000$-31,174,000$-26,357,000$-23,190,000$-22,475,000$-17,630,000$-18,044,000
    Interest Income$829,000$1.06M$1.20M$548,000$921,000$1.50M$1.91M$2.13M$1.07M$1.35M$0$1.44M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$1.44M
    Income Before Tax$-40,228,000$-37,284,000$-32,235,999$-29,561,000$-30,401,000$-26,639,000$-29,044,000$-24,248,000$-22,243,000$-20,346,000$-16,099,000$-16,599,000
    Income Tax Expense$0$0$0$0$0$0$1.33M$0$0$-1,332,000$22,188$69,586
    Net Income$-40,228,000$-37,284,000$-32,236,000$-29,561,000$-30,401,000$-26,639,000$-29,044,000$-24,248,000$-22,243,000$-20,346,000$-16,099,000$-16,599,000
    EBITDA$-40,129,000$-37,218,000$-32,195,999$-29,486,000$-30,368,000$-27,583,000$-28,974,000$-24,179,000$-22,174,000$-21,611,000$-16,033,000$-16,537,000
    EBIT$-40,228,000$-37,284,000$-32,235,999$-29,561,000$-30,401,000$-27,651,000$-29,044,000$-24,248,000$-22,243,000$-21,678,000$-16,099,000$-16,599,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SVRA

    News

    Savara Reports Molgramostim Benefits in Exploratory Lung Study

    Savara Inc. reported that its experimental drug molgramostim showed improvements in pulmonary gas transfer and lung imaging for patients with autoimmune pulmonary alveolar proteinosis (aPAP) in a retrospective analysis....

    MyChesCo•10/30/26•Somewhat-Bullish

    Savara Inc (YB4P.MU) Seasonal Returns Chart - Yahoo Finance

    The article displays a seasonal returns chart for Savara Inc (YB4P.MU) on Yahoo Finance. It provides historical seasonality data showing the average monthly price return from 2016 to 2026. The current quote for Savara...

    Yahoo! Finance Canada•10/30/26•Neutral

    Molgramostim Trial Update Might Change The Case For Investing In Savara (SVRA)

    Savara Inc. recently presented exploratory post-hoc data from its IMPALA trial at CHEST 2026, suggesting molgramostim treatment may offer descriptive improvements for aPAP patients with mild impairment. While these...

    Simply Wall St•10/30/26•Neutral

    SVRA Q3'26 Earnings: revenue estimate is 0 USD

    Savara, Inc. (SVRA) is scheduled to release its Q3'26 earnings on November 05, with an expected revenue estimate of 0 USD and an anticipated EPS of (0.16) USD. The earnings are projected to be disclosed at 7:00 AM ET...

    TradingView•10/30/26•Neutral

    Molgramostim Trial Update Might Change The Case For Investing In Savara (SVRA)

    Savara Inc. presented new exploratory data from a post-hoc IMPALA trial analysis for molgramostim in aPAP patients...

    Simply Wall St•10/29/26•Neutral

    SVRA Valuation and Fair Value

    P/E
    -8.4x
    Forward P/E
    0.4x
    P/FCF
    -11.1x
    PEG
    0.0x
    P/B
    8.5x
    See GNG's fair value

    SVRA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -63.3%
    ROE
    -105.5%
    FCF margin
    -11066000.0%
    FCF yield
    -9.0%

    SVRA Competitors

    CompanyTicker
    Harrow Health IncHROW
    Syndax Pharmaceuticals IncSNDX
    Janux Therapeutics IncJANX
    Immatics NVIMTX
    MoonLake ImmunotherapeuticsMLTX
    HealthStream IncHSTM
    QuidelOrtho CorpQDEL
    Jade Biosciences, Inc.JBIO

    Sector: Healthcare

    SVRA Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    2
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SVRA Bull Case vs Bear Case

    Bull case

    • 100.0% of SVRA's analyst ratings are Buy or Strong Buy.

    Bear case

    • SVRA beat EPS estimates in 12.5% of its last 8 reported quarters.

    SVRA Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -10.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.17
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 4 down

    SVRA Earnings Date

    SVRA reports Mar 11, 2027, after the close. The date is estimated.

    SVRA ETF Holders

    GNG tracks 9 ETFs that hold SVRA. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.16% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.03% of the fund
    3. iShares Biotechnology ETF (IBB), 0.03% of the fund
    4. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.02% of the fund
    Open the ETF Stock Exposure tool for SVRA

    See insider activity

    Frequently Asked Questions About SVRA

    When does SVRA report earnings?

    Savara Inc (SVRA) is expected to report earnings on Mar 11, 2027.

    Does SVRA pay dividends?

    Savara Inc (SVRA) does not currently pay a regular dividend.

    What is SVRA's market cap?

    Savara Inc (SVRA) has a market capitalization of $957.44M with a current stock price of $4.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In